<DOC>
	<DOCNO>NCT00797277</DOCNO>
	<brief_summary>The aim study compare efficacy safety intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg treatment acute agitate schizophrenic patient Taiwanese population .</brief_summary>
	<brief_title>Intramuscular ( IM ) Olanzapine Versus IM Haloperidol Plus Lorazepam Acute Agitation Schizophrenia</brief_title>
	<detailed_description>To date , publish report clinical study IM olanzapine versus IM haloperidol plus lorazepam acute schizophrenia patient moderate severe degree agitation . The latter combination treatment use quite often traditional way treat agitate schizophrenia patient . Study Design : This randomize , active-controlled , parallel-group study , consist screen treatment phase . Patients complete screening phase would randomize receive either 10mg olanzapine IM 5 mg haloperidol plus 2 mg lorazepam IM . The ratio randomization 1:1 . Treatment assignment base computer-generated randomization code supply central unit block design . Patients receive maximum 3 injection within first 24-hour period . Second third injection use clinical judgment investigator . The second injection allow 2-hour elapsed since first injection . The third injection allow 4-hour pass since second injection . Prohibited medication include antiarrythmics , antipsychotic , antidepressant , anticonvulsant , antiemetic , psychotropic drug . Efficacy Assessments : Patients assess study investigator screen visit 15 , 30 , 60 , 120 minute first injection . The primary efficacy measure PANSS-EC , include item tension , uncooperativeness , hostility , poor impulse control , excitement derive PANSS originator use principal-components factor analysis . Agitation assess Agitation-Calmness Evaluation Scale ( ACES ) ( Copyright 1998 , Eli Lilly Company ; right reserve ) . Clinical Global Impression-Severity（CGI-S）scale37 use assess general psychiatric condition . For patient , rater conduct assessment throughout study . Safety assessment : During 24-hour treatment period , safety assess clinical examination laboratory investigation , record spontaneously report adverse event , complete Simpson-Angus Scale ( SAS ) Barnes Akathisia Scales ( BAS ) . Statistical Procedures : The efficacy analyse base intent treat ( ITT ) population define consist randomized subject . The last observation carry forward ( LOCF ) dataset use estimate miss data . Data analyse use statistical program R Language version 2.8.0 ( http : //www.r-project.org/ ) , significance set p &lt; .05 . Demographic characteristic clinical parameter baseline compare treatment group use t-test continuous variable chi-square test categorical variable . The primary treatment comparison 2-hour PANSS-EC score first injection . Continuous efficacy safety data evaluate multiple linear regression , adjust treatment group , center , treatment-by-center interaction . The treatment-by-center interaction test 0.10 significant level drop model statistically significant . To compare number difference adverse event two treatment group , Fisher 's exact test use due low cell count .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Men nonpregnant , nonlactating woman age 18 65 year primary diagnosis schizophrenia ( DSMIV ) hospitalize due acute relapse clinically agitate minimum total score ≧ 14 five item PANSSEC least one individual item score ≧ 4 use 17 scoring system prior first IM injection study drug . female subject either pregnant breastfeeding ; patient acute , serious unstable medical condition ; treatment benzodiazepine within 4 hour prior first IM study drug administration ; treatment injection depot neuroleptic within 1 injection interval prior study drug administration ; history allergic reaction intolerance study medication ( ) ; know diagnosis dementia type , define DSMIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>olanzapine</keyword>
	<keyword>haloperidol</keyword>
	<keyword>lorazepam</keyword>
	<keyword>agitation</keyword>
</DOC>